{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2007"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms","Patients with metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer","Patients With Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2042621"],"location":["Sweden","Austria","Belgium","France","Germany"],"study_start_month":["5"],"keyword":["Panitumumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer","description":"To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line therapy for metastatic colorectal cancer (mCRC).","dates":{"creation":"2007-05-15"},"accession":"2042621","cross_references":{"ClinicalTrials___gov":["NCT00508404"],"EU Clinical Trials Register":["2006-006739-36"]}}